Status:
COMPLETED
Prevalence of Hyperprolactinemia in Systemic Scleroderma
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Association pour la Formation et la Recherche en Médecine Interne (AFORMI)
Conditions:
Sclerosis, Systemic
Scleroderma
Eligibility:
All Genders
18+ years
Brief Summary
Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there ...
Eligibility Criteria
Inclusion
- Scleroderma patients:
- man or woman over 18 years old
- with systemic sclerosis meeting ACR-EULAR 2013 criteria
- having given his no opposition
- being social insured
- Healthy subjects:
- man or woman over 18 years old
- donation of blood to the EFS
- matched on age (+/- 5 years) and sex
- having given his no opposition
Exclusion
- Man or woman under 18 years old
- Pregnant or breastfeeding women
- Receiving medical treatment inducing dysfunction of the hypothalamic pituitary axis
- Refusing or unable to give no objection
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 12 2021
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT04746313
Start Date
March 1 2021
End Date
May 12 2021
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037